In contrast, in some phase II studies, including patients with non-small cell lung cancer (NSCLC) (Sequist et al., 2010[40]) and HER2-positive breast cancer (Modi et al., 2013[30]), IPI-504 had an acceptable safety profile, with infrequent transaminase elevations. Here, ERBB2 is linked to breast carcinoma.